HCPCS
J9047
1 mg = 1 unit
Phase 1
Identify what you're billing
Confirm regimen, BSA dose, cycle position (step-up vs target), and cardiac status before billing.
Proteasome inhibitor class — where Kyprolis fits NCCN verified May 2026
Kyprolis is the second-generation, irreversible PI — greater efficacy than Velcade with a different toxicity profile.
| Drug | HCPCS / Benefit | Generation / Mechanism | Route / Schedule | Key trade-off |
|---|---|---|---|---|
| Kyprolis (carfilzomib) | J9047 (medical) |
2nd-gen irreversible epoxyketone PI | IV 10–30 min; weekly or twice-weekly per regimen | Greater efficacy + better neuropathy profile, but higher cardiac toxicity |
| Velcade (bortezomib, brand) | J9041 (medical, 0.1 mg unit) |
1st-gen reversible boronic acid PI | SC (preferred) or IV bolus; weekly or twice-weekly | Peripheral neuropathy is dose-limiting; cardiac AEs less common |
| Bortezomib generic | J9049 (medical, 0.1 mg unit) |
1st-gen reversible boronic acid PI | SC or IV bolus; same as Velcade | ~44% cheaper than J9041; preferred by most payers |
| Boruzu (bortezomib premixed) | J9054 (medical, 0.1 mg unit) |
1st-gen reversible boronic acid PI | Premixed solution; no reconstitution | Workflow-driven choice; same indications as Velcade |
| Ninlaro (ixazomib) | Pharmacy benefit — oral capsule (no J-code) | 1st-gen reversible boronic acid PI; oral | Oral once-weekly; days 1, 8, 15 of 28-day cycle | Convenience over IV/SC; pharmacy benefit, not medical |
Why pick Kyprolis over Velcade? Greater efficacy in relapsed/refractory MM (longer PFS in
head-to-head trials) and a substantially better peripheral neuropathy profile. Patients who developed
dose-limiting neuropathy on bortezomib often tolerate carfilzomib well. Common combo partners include
Darzalex (J9145), Empliciti (J9176), and
Sarclisa (J9227) — the monoclonal antibody backbones of modern triplet
and quadruplet R/R MM regimens.
Why payers steer cardiac-comorbid patients toward Velcade. Kyprolis cardiac AE rates
(heart failure, MI, hypertension) exceed those seen with bortezomib. Payers with active cardiac
comorbidity flags often require documented cardiology clearance + recent echo before approving Kyprolis,
and some plans default to bortezomib for patients >65 with cardiac history.
Class is not interchangeable for billing. Each PI has its own J-code, ASP, and PA
criteria. Switching between Kyprolis and Velcade is a regimen change that requires fresh PA in most
plans. Ninlaro is a pharmacy-benefit oral, not a medical-benefit injectable — coverage falls under
the pharmacy formulary, not the medical drug policy.
Dosing by regimen NCCN MM v.2.2026 / FDA label
Four major Kyprolis regimens for relapsed/refractory MM. All use BSA-based dosing; dose, schedule, and infusion duration vary.
| Regimen | Dose (target) | Schedule | Cycle | Infusion time |
|---|---|---|---|---|
| Kd (carfilzomib + dex), R/R MM | 56 mg/m² IV (or 70 mg/m²) | Day 1, 8, 15 (weekly × 3) per 28-day cycle | 28 days | 30 min |
| KRd (carfilzomib + lenalidomide + dex), R/R MM | 27 mg/m² IV | Days 1, 2, 8, 9, 15, 16 (twice weekly × 3 weeks) | 28 days | 10 min |
| Kdara (carfilzomib + daratumumab + dex), R/R MM | 56 mg/m² IV (or 70 mg/m²) | Day 1, 8, 15 weekly per 28-day cycle | 28 days | 30 min |
| Kpd (carfilzomib + pomalidomide + dex), R/R MM | 27 mg/m² IV | Days 1, 2, 8, 9, 15, 16 (twice weekly × 3 weeks) | 28 days | 10 min |
BSA-based unit math — convert mg to J9047 units
| Patient BSA | Kd 56 mg/m² dose | J9047 units billed | Vial usage | JW waste units |
|---|---|---|---|---|
| 1.5 m² | 84 mg | 84 | 1 × 60 mg + 1 × 30 mg | 6 (90 mg used) |
| 1.7 m² | 95.2 mg | 95 | 1 × 60 mg + 2 × 30 mg | 25 (120 mg used) |
| 1.92 m² (avg) | 107.5 mg | 108 | 1 × 60 mg + 2 × 30 mg | 12 (120 mg used) |
| 2.0 m² | 112 mg | 112 | 1 × 60 mg + 2 × 30 mg | 8 (120 mg used) |
| 2.2 m² | 123.2 mg | 123 | 2 × 60 mg + 1 × 30 mg | 27 (150 mg used) |
Worked example — Kd 56 mg/m² weekly, 1.92 m² patient, post step-up
# Per-dose math (56 mg/m² × 1.92 m² = 107.5 mg)
Drug administered: 108 mg IV over 30 minutes
J9047 units billed: 108
HCPCS: J9047 · Modifier: JW (waste)
Vials used: 1 × 60 mg + 2 × 30 mg = 120 mg total → 12 mg waste = 12 units JW
Admin: 96413 (chemo IV, ≤1 hr)
# Per 28-day cycle (3 weekly doses on Kd; D1, D8, D15)
Total drug units administered: 324 (3 × 108)
Total waste units: 36 (3 × 12)
Drug cost (Q2 2026 ASP+6%, J9047 $56.239): 324 × $56.239 = $18,221.44 drug-only per cycle
Including waste reimbursement: 360 × $56.239 = $20,246.04 (waste billed on JW line at same rate)
# Annualized (~13 cycles/year)
Drug cost: ~$237,000/year drug-only
After ~2% sequestration: ~$232,000/year actual paid
Drug administered: 108 mg IV over 30 minutes
J9047 units billed: 108
HCPCS: J9047 · Modifier: JW (waste)
Vials used: 1 × 60 mg + 2 × 30 mg = 120 mg total → 12 mg waste = 12 units JW
Admin: 96413 (chemo IV, ≤1 hr)
# Per 28-day cycle (3 weekly doses on Kd; D1, D8, D15)
Total drug units administered: 324 (3 × 108)
Total waste units: 36 (3 × 12)
Drug cost (Q2 2026 ASP+6%, J9047 $56.239): 324 × $56.239 = $18,221.44 drug-only per cycle
Including waste reimbursement: 360 × $56.239 = $20,246.04 (waste billed on JW line at same rate)
# Annualized (~13 cycles/year)
Drug cost: ~$237,000/year drug-only
After ~2% sequestration: ~$232,000/year actual paid
Round to whole mg. CMS expects billed J9047 units in whole-mg increments. A 107.5 mg
administered dose bills as 108 units (round up per CMS waste/round policy). Pharmacy can prepare to the
nearest mg with the 2 mg/mL reconstituted concentration; document the actual dose given to support both
administered and JW waste units. Vial combinations are 10/30/60 mg only — pharmacy combines vials to
the smallest total that covers the calculated dose.
Cycle 1 step-up dosing schedule FDA label verified May 2026
Every Kyprolis regimen requires a step-up loading on cycle 1, day 1 and 2 to assess tolerability before escalating to target dose.
Cycle 1 step-up applies to all regimens. Day 1 and Day 2 of cycle 1 use a 20 mg/m²
loading dose regardless of target. Day 8 onward escalates to the target dose for the regimen
(27, 56, or 70 mg/m²). The step-up is intended to assess infusion-related reactions, cardiac
tolerance, and hydration response. Subsequent cycles use target dose throughout.
| Regimen | C1 D1 | C1 D2 | C1 D8 onward | C2 onward |
|---|---|---|---|---|
| Kd (target 56 mg/m² weekly) | 20 mg/m² | 20 mg/m² | 56 mg/m² (D8, D15) | 56 mg/m² (D1, D8, D15) |
| Kd (target 70 mg/m² weekly) | 20 mg/m² | 20 mg/m² | 70 mg/m² (D8, D15) | 70 mg/m² (D1, D8, D15) |
| KRd (target 27 mg/m² twice weekly) | 20 mg/m² | 20 mg/m² | 27 mg/m² (D8, D9, D15, D16) | 27 mg/m² (D1, D2, D8, D9, D15, D16) |
| Kdara (target 56 or 70 mg/m² weekly) | 20 mg/m² | 20 mg/m² | Target dose (D8, D15) | Target dose (D1, D8, D15) |
| Kpd (target 27 mg/m² twice weekly) | 20 mg/m² | 20 mg/m² | 27 mg/m² (D8, D9, D15, D16) | 27 mg/m² (D1, D2, D8, D9, D15, D16) |
Bill the step-up dose at the actual mg administered, not the target. A 1.92 m²
patient on Kd C1 D1: 20 mg/m² × 1.92 = 38.4 mg administered → 38 units of J9047. Vial usage:
1 × 30 mg + 1 × 10 mg = 40 mg → 2 units JW waste. Step-up doses produce smaller total units
but the same per-mg ASP applies.
Hydration protocol — chair-time impact FDA label verified May 2026
Pre and post-hydration is required during cycle 1. This is the single biggest driver of Kyprolis chair time and a frequent billing oversight.
Cycle 1 hydration adds 60+ minutes to chair time. A 30-minute Kyprolis infusion becomes
a 90–120 minute encounter once 250–500 mL of pre-hydration and 250–500 mL of post-hydration
are included. Most centers also keep the line open with maintenance fluid through the post-hydration
period. Plan chair-time scheduling accordingly.
| Cycle / Dose | Pre-hydration | Post-hydration | Reducible? |
|---|---|---|---|
| Cycle 1, all doses | 250–500 mL IV NS pre-Kyprolis | 250–500 mL IV NS post-Kyprolis | No — required |
| Cycle 2 onward (well-tolerated) | Reduce or omit per clinician | Reduce or omit per clinician | Yes if no signs of TLS / cardiac / renal events |
| Dose escalation cycles (e.g., Kd 56 → 70) | Reinstate full 250–500 mL | Reinstate full 250–500 mL | Resume protocol on escalation |
CPT for pre/post-hydration
| Code | Description | When |
|---|---|---|
96360 | IV infusion, hydration, initial 31 min–1 hr | Initial hydration when no other infusion service is the "initial" on the encounter |
96361 | IV hydration, each additional hour | Additional hydration time beyond first hour, or sequential to chemo |
96365 | Therapeutic IV non-chemo, initial 1 hr | NOT for the Kyprolis line itself; potential for concurrent supportive meds |
Hierarchy rule: When chemotherapy admin (96413) is performed on the same encounter,
chemo is the "initial" service. Pre and post-hydration use sequential codes (96361) rather than
the initial 96360. Sequencing matters for proper unit count and reimbursement — verify with your MAC's
infusion-coding hierarchy guidance.
Pre-medication: dexamethasone 4 mg PO/IV. Required during cycle 1 and any escalation
cycle, ~30 minutes before each Kyprolis dose. Reduces infusion reactions. Many regimens (Kd, KRd, Kdara,
Kpd) include dexamethasone as a backbone agent on the same days, so the pre-med dose may overlap with the
regimen's scheduled steroid.
NDC reference FDA NDC Directory verified May 2026
| NDC (10/11-digit) | Package | Use |
|---|---|---|
76310-005-01 / 76310-0005-01 |
10 mg lyophilized single-dose vial — 1 vial / carton | Step-up dosing; small adjustments to BSA-calculated doses |
76310-006-01 / 76310-0006-01 |
30 mg lyophilized single-dose vial — 1 vial / carton | Most common workhorse vial across all regimens |
76310-007-01 / 76310-0007-01 |
60 mg lyophilized single-dose vial — 1 vial / carton | Used in 56/70 mg/m² regimens to minimize vial count |
NDCs verified at most recent label review. Amgen periodically updates carton/labeler
codes — verify the NDC printed on the dispensed vial matches the claim. Submit the 11-digit NDC with
the N4 qualifier. Use carton-level NDC, not internal pharmacy compounding NDC.
Reconstitution: All three vials reconstitute with sterile water for injection to
2 mg/mL. Pharmacy combines vials to reach the calculated mg dose. The 60 mg vial is the largest available
— doses >60 mg always require multi-vial combinations.
Phase 2
Code the claim
Chemo IV admin codes apply (96413 + 96415 if extended). Hydration billed separately as sequential infusion.
Administration codes CPT verified May 2026
Carfilzomib is anti-neoplastic — bill chemo admin codes, not therapeutic IV.
| Code | Description | When to use |
|---|---|---|
96413 |
Chemotherapy administration, IV infusion technique; up to 1 hour, single or initial substance/drug | Primary code for Kyprolis IV. 10–30 minute infusion fits within the 1-hour window. |
96415 |
Chemotherapy administration, IV infusion; each additional hour | Add when total chair time on combo regimens (e.g., Kdara: Kyprolis + daratumumab same day) exceeds 1 hour. |
96360 / 96361 |
IV hydration, initial / each additional hour | Pre and post-hydration (cycle 1, escalation cycles). 96361 sequential when chemo is the initial service. |
96365 / 96366 |
Therapeutic IV infusion (non-chemo) | NOT appropriate for carfilzomib itself. Use chemo admin per AMA classification. |
96372 |
Therapeutic SC/IM injection | NOT appropriate. Kyprolis has no SC formulation; IV only. |
Combo regimen sequencing: On Kdara days when Kyprolis and Darzalex are both administered,
bill 96413 once for the "initial" chemo admin and 96417 (each additional sequential infusion of a
different chemo drug) for the second drug. Verify your MAC's exact sequencing rules for multi-drug
chemo encounters.
Modifiers CMS verified May 2026
JW — required on most Kyprolis claims (BSA dosing → partial-vial waste)
JW reports the discarded portion of a single-dose vial. Kyprolis vials are 10, 30, and 60 mg only; BSA-calculated doses rarely match whole-vial multiples, so partial-vial waste is the norm. Example: a 1.92 m² patient at 56 mg/m² = 107.5 mg administered; pharmacy combines 1 × 60 mg + 2 × 30 mg (120 mg total), administering 108 mg and discarding 12 mg. Bill 108 units of J9047 (administered) + a separate JW line for 12 units (waste). Wasted drug is reimbursable but must be reported on a separate line.
JZ — only when the BSA-calculated dose exactly matches whole vials
JZ applies on single-dose container claims when zero drug is discarded. With Kyprolis vial sizes (10, 30, 60 mg), JZ is rare — only when BSA happens to equal exact multiples that map cleanly. One of JZ or JW must appear on every J9047 claim per CMS's July 2023 single-dose container policy.
Modifier 25 — same-day E/M
Use modifier 25 on the E/M code when a significant, separately identifiable evaluation and management service is performed on the same day as the infusion. Cardiac monitoring (BP, symptom assessment) performed during the routine pre-infusion encounter is bundled.
340B modifiers (JG, TB)
For 340B-acquired Kyprolis, follow your MAC's current 340B modifier policy. Amgen's billing guide does not provide 340B-specific instructions.
Common error: Forgetting the JW line and billing only administered units. CMS audits
catch this — bill the JW line with the actual discarded units alongside the administered line. Both
are reimbursable. Single-dose vial waste documentation requirements apply.
ICD-10-CM by indication FY2026 verified May 2026
Multiple myeloma is the dominant indication. Kyprolis is approved for relapsed/refractory MM in adults who have received ≥1 prior line (combo regimens) or ≥2 prior lines (monotherapy).
| Code | Indication | Notes |
|---|---|---|
C90.00 | Multiple myeloma not having achieved remission | Active disease at presentation; PA must include line of therapy + prior regimens |
C90.01 | Multiple myeloma in remission | Use when continuing therapy in remission state per regimen plan |
C90.02 | Multiple myeloma in relapse | Most common ICD-10 for Kyprolis indication; required for R/R PA |
C90.1x | Plasma cell leukemia | Off-label rare subtype; PA + medical necessity letter required |
C90.3x | Solitary plasmacytoma | Off-label; rarely covered without medical necessity justification |
Regimen acronym + line of therapy required. Most major payers will deny on ICD-10 alone.
PA must include: (1) ICD-10, (2) line of therapy (e.g., 2L, 3L), (3) prior regimens with response/failure
documented, (4) regimen acronym (Kd, KRd, Kdara, Kpd), (5) target dose level (56 vs 70 mg/m² for Kd /
Kdara), and (6) baseline cardiac assessment for Kyprolis specifically.
Site of care & place of service Verified May 2026
Kyprolis is typically restricted to academic / comprehensive cancer centers and large hospital-based oncology infusion suites because of cardiac monitoring requirements. UnitedHealthcare, Aetna, and most major BCBS plans run site-of-care UM, but the cardiac toxicity profile gives many centers grounds to defend HOPD administration in the cycle 1 / escalation phase.
| Setting | POS | Claim form | Payer steering |
|---|---|---|---|
| Physician oncology office | 11 | CMS-1500 / 837P | Acceptable post-cycle 1 if cardiac stable; preferred by commercial UM |
| Ambulatory infusion suite (AIC) | 49 | CMS-1500 / 837P | Acceptable post-cycle 1; preferred by commercial UM |
| Oncology ASC | 24 | CMS-1500 / 837P | Acceptable |
| Hospital outpatient (on-campus) | 22 | UB-04 / 837I | Common for cycle 1 + escalation; payer pushback after stable cycles |
| Hospital outpatient (off-campus PBD) | 19 | UB-04 / 837I | Disfavored after first 3 months |
| Patient home | 12 | CMS-1500 (with home infusion) | Not appropriate — cardiac monitoring requirement |
Defensible HOPD argument: Cycle 1 cardiac monitoring + extensive pre/post-hydration +
infusion-reaction risk justify HOPD setting in many cases. Submit medical necessity letter citing FDA
label cardiac W&P + cycle 1 hydration protocol + infusion reaction history if available.
Claim form field mapping Amgen 2025
From Amgen Assist 360 HCP coding & reimbursement guidance.
| Information | CMS-1500 box | Notes |
|---|---|---|
| NPI | 17b | Rendering provider |
| NDC qualifier + 11-digit NDC + UoM + qty | 24A shaded area | N4 + carton NDC + ML + total volume (e.g., 60 mL for 120 mg @ 2 mg/mL) |
| HCPCS J9047 + JW (or JZ if no waste) | 24D (drug line) | JW typical for adult BSA dosing with 10/30/60 mg vials |
| Drug units (administered) | 24G | Whole-mg increments; e.g., 108 units for 108 mg administered |
| JW waste line | 24D (separate line) | Discarded mg as separate units billing |
| CPT 96413 (admin line) | 24D (admin line) | 10–30 min infusion fits within 1-hour window |
| CPT 96361 (hydration, sequential) | 24D (hydration line) | Pre / post-hydration in cycle 1 |
| ICD-10 | 21 | C90.02 (relapse) most common; C90.00 / C90.01 per remission status |
| PA number | 23 | Required by all major payers |
Phase 3
Get paid
Cardiac assessment + line of therapy + regimen acronym are the three keys to first-pass approval.
Payer policy snapshot + cardiac documentation Reviewed May 2026
All major payers require PA + prior MM therapy + cardiac baseline. Concurrent PA on combo agents (lenalidomide/pomalidomide REMS, daratumumab) often determines whether the regimen actually starts.
| Payer | PA? | Prior therapy / cardiac | Combo / regimen requirements |
|---|---|---|---|
| UnitedHealthcare Oncology Med Coverage Policy |
Yes | ≥1 prior MM therapy (combo) or ≥2 (mono); cardiac assessment docs (echo, BP); cardiology consult if comorbid history | Concurrent PA on lenalidomide REMS (KRd), pomalidomide REMS (Kpd), or daratumumab (Kdara). All combo agents must clear before regimen starts. |
| Aetna CPB + Medical Drug policies |
Yes | R/R MM with prior therapy documented; cardiac baseline required; HF or recent MI typically excludes | Site-of-care UM applies; combo agent PA chains required (lenalidomide, pomalidomide, daratumumab) |
| BCBS plans Vary by plan |
Yes | Generally aligned with NCCN MM guidelines + FDA label cardiac W&P | Plan-specific; most require regimen acronym + line of therapy + cardiac status |
Cardiac documentation required by most payers
- Baseline ECG (standard in MM workup; payers expect on file)
- Echocardiogram if symptomatic or with cardiac history; LVEF documentation
- Baseline BP (hypertension control documented)
- Cardiology consult note for patients >65 with cardiac comorbidity, HF history, or recent MI
- Ongoing BP monitoring at every visit during cycle 1; documented in the chart
Step therapy
Generally NOT required to step through Velcade first for FDA-labeled R/R MM — both bortezomib and carfilzomib are NCCN preferred PI options. Some payers do require documentation of why bortezomib is not appropriate (prior failure, intolerable neuropathy, contraindication). Cardiac comorbidity may reverse this and trigger payer steering toward Velcade.
Medicare reimbursement CMS Q2 2026 (live)
Quarterly ASP from CMS Part B Drug Pricing File. Refreshes automatically each quarter.
Q2 2026 payment snapshot — J9047
Effective April 1 – June 30, 2026 · Based on 4Q25 ASP submissions
ASP + 6%
$56.239
per mg / per unit
108 mg dose (Kd 56 mg/m² @ 1.92 m²)
$6,073.81
108 units × ASP+6%
52 mg dose (KRd 27 mg/m² @ 1.92 m²)
$2,924.43
52 units × ASP+6%
Annualized cost (drug-only): Kd 56 mg/m² weekly × 13 cycles × 3 doses/cycle ≈
4,200 mg/year for an average-BSA patient. At Q2 2026 J9047 ASP+6%: ~$237,000/year drug-only.
After ~2% sequestration: ~$232,000/year actual paid. KRd twice-weekly is lower per dose but more doses per
cycle — total annual mg is comparable.
Coverage
No NCD specific to carfilzomib. Coverage falls under MAC LCDs for biologics + the generic drug-coverage framework. All MACs cover J9047 for FDA-approved on-label indications with appropriate ICD-10, line of therapy, regimen, and cardiac documentation.
Code history
- J9047 — permanent code, "Injection, carfilzomib, 1 mg" (effective after initial Kyprolis approval July 2012)
Patient assistance — Amgen Assist 360 Amgen verified May 2026
- Amgen Assist 360 (HCP support): 1-888-427-7478 / amgenassist360.com — benefits investigation, prior authorization assistance, appeal support, denial support
- Kyprolis Co-Pay Card: commercial $5 first dose, ongoing copay support up to $25,000/year (excludes Medicare, Medicaid, federal program patients)
- Amgen Safety Net Foundation: free product for uninsured / underinsured patients meeting income requirements (501(c)(3))
- Foundations for Medicare patients: PAN, HealthWell, CancerCare, LLS Co-Pay — verify open MM funds quarterly
- Web: amgenassist360.com / kyprolis.com
Need to model what a specific patient will actually pay after Amgen copay assistance, deductible,
coinsurance, and OOP max? Run a CareCost Estimate — J9047 pre-loaded.
Phase 4
Fix problems
Cardiac toxicity is the dominant clinical safety concern; missing JW and missing cardiac docs are the dominant billing/PA problems.
Cardiac toxicity — the class differentiator FDA label verified May 2026
Cardiac toxicity is the dominant safety concern with Kyprolis. The FDA label includes
prominent Warnings & Precautions for cardiac arrest, myocardial infarction, new or worsening heart
failure, myocardial ischemia, and hypertension (including hypertensive crisis). Rates exceed those seen
with Velcade (bortezomib). Treat as a boxed-warning analog: every cycle 1 visit needs documented BP and
symptom assessment; baseline echo if symptomatic or cardiac history; cardiology consult for high-risk
patients. This is the dominant reason payers steer cardiac-comorbid MM patients toward Velcade.
Cardiac monitoring expectations (per FDA label)
| Time point | What to monitor / document |
|---|---|
| Baseline (pre-cycle 1) | BP, HR, ECG; echocardiogram if symptomatic or cardiac history; cardiology consult for HF history, recent MI, uncontrolled HTN |
| Cycle 1, every dose | BP pre and post-infusion; symptoms (chest pain, dyspnea, edema); document in chart |
| Cycle 2 onward | BP at every visit; symptom screening; repeat echo if new symptoms or BP not controlled |
| Dose escalation (e.g., Kd 56 → 70) | Reinstate cycle 1 monitoring intensity for the escalation cycle |
Other key Warnings & Precautions
- Thrombotic microangiopathy / TTP — rare but serious; monitor CBC + LDH + creatinine; discontinue if confirmed
- Pulmonary toxicity — pneumonitis, ARDS, pulmonary edema; monitor for dyspnea, hypoxia
- Pulmonary hypertension — reported with Kyprolis; baseline + symptom-driven evaluation
- Infusion reactions — fever, rigors, dyspnea, hypotension; dexamethasone pre-med reduces incidence
- Tumor lysis syndrome — high-burden disease; pre/post-hydration + monitoring
- Hepatic events — LFT monitoring; dose modifications for moderate/severe hepatic impairment
- Renal toxicity — pre/post-hydration mitigates; monitor creatinine
- Embryo-fetal toxicity — contraception required for both partners during treatment + post-treatment window
- Venous thromboembolism — especially in combo with lenalidomide; thromboprophylaxis per regimen
Hypertension is often undertreated and triggers payer pushback. Aggressive BP management
(target <140/90 per most payer policies; lower if cardiac history) is required to maintain Kyprolis
coverage. Document antihypertensive regimen + BP readings at every visit. Uncontrolled HTN is the most
common reason for mid-treatment payer review.
Common denials & how to fix them
| Denial reason | Common cause | Fix |
|---|---|---|
| Cardiac assessment missing | PA submitted without baseline BP / echo / cardiology note | Submit baseline cardiac docs + retroactive PA. Schedule echo and cardiology review BEFORE submitting PA for any patient with cardiac history. |
| Wrong admin code (96365) | Therapeutic IV billed instead of chemo IV | Resubmit with 96413. Carfilzomib is anti-neoplastic per CPT classification. |
| Missing JW for waste | Partial-vial dose without JW line | Add JW line for discarded units. Most BSA doses produce waste with the 10/30/60 mg vials. |
| Missing JZ on full-vial dose | Single-dose vial claim without JZ when no waste | Add JZ if BSA-calculated dose exactly matches whole vials. Required since 7/1/2023. |
| Hydration not coded correctly | 96360 billed as initial when chemo is the initial service | Use 96361 sequential to chemo 96413; hierarchy rule applies. Verify MAC sequencing guidance. |
| Step-up dose not documented | C1 D1 / D2 billed as target dose | Submit chart note + bill the actual mg administered (20 mg/m² loading), not the target. Step-up is required per FDA label. |
| Combo regimen not documented | ICD-10 alone submitted without Kd / KRd / Kdara / Kpd regimen | Submit complete clinical history: line of therapy, combo agents, prior therapies, response. |
| Lenalidomide REMS hold | KRd regimen blocked because lenalidomide PA not approved | Submit lenalidomide REMS + PA in parallel with Kyprolis PA. Both must clear before KRd starts. |
| Pomalidomide REMS hold | Kpd regimen blocked because pomalidomide PA not approved | Same as above for Kpd; pomalidomide REMS in parallel. |
| Daratumumab PA missing | Kdara regimen blocked because daratumumab PA not approved | Submit daratumumab PA in parallel with Kyprolis PA. Both must clear before Kdara starts. |
| Site of care (HOPD) post-cycle 1 | HOPD administration after first 3 months on commercial plan with site-of-care UM | Move to office (POS 11) or AIC (POS 49) post-cycle 1 if cardiac stable. Submit medical necessity letter if HOPD required. |
| Hypertension uncontrolled | Mid-treatment payer review on documented uncontrolled BP | Document antihypertensive regimen + recent controlled BP readings before resubmitting / continuing therapy. |
Frequently asked questions
What is the HCPCS code for Kyprolis?
Kyprolis (carfilzomib IV) is billed under HCPCS J9047 — "Injection, carfilzomib, 1 mg."
Each milligram equals one billable unit. Unlike Velcade (J9041) which uses a 0.1 mg unit basis, Kyprolis
uses a straightforward 1 mg = 1 unit.
How many units do I bill for a Kyprolis dose?
Bill the actual mg administered as units (1 mg = 1 unit), rounded per CMS guidance. For a patient at
1.92 m² BSA on the Kd 56 mg/m² weekly regimen: 56 × 1.92 = 107.5 mg administered, billed as
108 units of J9047. Vials are 10, 30, and 60 mg lyophilized — pharmacy
combines vials to reach the calculated dose, and partial-vial waste is the norm. Bill the JW modifier for
discarded units.
What administration CPT do I use for Kyprolis?
CPT 96413 — "Chemotherapy administration, IV infusion technique; up to 1 hour, single
or initial substance/drug" — is the primary code. For higher doses (56–70 mg/m²) infused
over 30 minutes, 96413 alone covers the chair time. For combo regimens or extended pre/post-hydration,
96415 (each additional hour) may apply. Do NOT use 96365 (therapeutic IV non-chemo).
Do I bill JZ or JW for Kyprolis?
Bill JW on virtually every adult Kyprolis claim. Vials are 10, 30, and 60 mg single-dose;
BSA-calculated doses rarely match whole-vial multiples. Example: 1.92 m² patient at 56 mg/m² =
107.5 mg administered → 1 × 60 mg + 2 × 30 mg = 120 mg total → 108 units billed +
12 units JW waste. JZ applies only when the BSA-calculated dose exactly matches whole vials
(rare). One of JZ or JW must be on every J9047 claim per CMS's July 2023 single-dose container policy.
What is the Medicare reimbursement for J9047?
For Q2 2026, the Medicare Part B payment limit for J9047 is $56.239 per mg (ASP + 6%). A 108 mg dose reimburses at approximately $6,073.81 per administration. Annualized cost on the Kd 56 mg/m² weekly regimen runs approximately ~$237,000/year for an average-BSA patient. Sequestration (~2%) reduces actual paid to roughly ASP + 4.3%.
What are the main Kyprolis regimens?
Four major combo regimens for relapsed/refractory MM: Kd (Kyprolis + dex) at 56 or 70 mg/m² IV weekly; KRd (Kyprolis + lenalidomide + dex) at 27 mg/m² IV twice weekly; Kdara (Kyprolis + daratumumab + dex) at 56 or 70 mg/m² IV weekly; Kpd (Kyprolis + pomalidomide + dex) at 27 mg/m² IV twice weekly. All regimens require a cycle 1 step-up (20 mg/m² on D1 and D2 of cycle 1, then escalate to target dose on D8).
How does Kyprolis compare to Velcade?
Kyprolis (carfilzomib, J9047) is a second-generation epoxyketone proteasome inhibitor
with irreversible binding — more potent than Velcade (bortezomib, J9041),
which is a first-generation reversible boronic acid PI. Kyprolis offers greater efficacy in
relapsed/refractory MM and a substantially better peripheral neuropathy profile. The trade-off is cardiac
toxicity: Kyprolis has higher rates of cardiac arrest, MI, heart failure, and hypertension. Many payers
favor Velcade for patients with cardiac comorbidities. Switching is a regimen change requiring fresh PA.
What is the cardiac toxicity warning for Kyprolis?
The FDA label includes prominent Warnings & Precautions for cardiac arrest, myocardial infarction, new or worsening heart failure, myocardial ischemia, and hypertension (including hypertensive crisis). Rates exceed those seen with Velcade. Baseline cardiac assessment (echo if symptomatic, BP) is required before initiation, and BP monitoring is recommended at every visit. Patients with active cardiac disease, recent MI, or uncontrolled hypertension are typically excluded. This is the dominant reason payers steer cardiac-comorbid MM patients toward Velcade.
Why does Kyprolis require pre-hydration?
Pre-hydration (250–500 mL IV fluids) is required before AND after each Kyprolis dose during cycle 1 to reduce risk of tumor lysis syndrome and renal toxicity. Patients also receive dexamethasone 4 mg PO/IV pre-dose during cycle 1 and any dose-escalation cycle. Hydration may be reduced or eliminated in subsequent cycles if tolerated. This protocol significantly extends chair time — a 30-minute infusion becomes a 90+ minute encounter. CPT 96361 (sequential hydration) may apply alongside the 96413 chemo IV admin.
What ICD-10 codes do I use for Kyprolis?
Multiple myeloma is the dominant indication: C90.00 (not in remission), C90.01
(in remission), C90.02 (in relapse). C90.02 is most common for the R/R MM indication. Most
payers also require line of therapy, regimen acronym (Kd, KRd, Kdara, Kpd), and cardiac status in the PA.
ICD-10 alone is not sufficient.
Reference
Sources & methodology
Every claim on this page is sourced. Methodology and review history below.
Source documents
- Amgen — Kyprolis HCP page
- DailyMed — KYPROLIS (carfilzomib) Prescribing Information
- Amgen Assist 360 — HCP & Patient Support
- Amgen — Kyprolis product page
- CMS — Medicare Part B Drug ASP Pricing File
- NCCN Clinical Practice Guidelines — Multiple Myeloma v.2.2026
- SEER CanMED — HCPCS J9047 reference
- UnitedHealthcare — Oncology Medication Clinical Coverage Policy
- Aetna — Medical Drug + CPB policies for proteasome inhibitors
- FDA National Drug Code Directory
About this page
We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.
Found an error? Email hello@carecostestimate.com.
Refresh cadence
| Element | Cadence | How it's refreshed |
|---|---|---|
| Medicare ASP pricing | Quarterly | Auto-bound to CareCost ASP layer; updates on CMS file release. |
| Payer policies (UHC, Aetna, BCBS) | Semi-annual | Manual review against published payer policy documents. |
| HCPCS / CPT / modifier rules | Annual | Reviewed against CMS HCPCS quarterly files, AMA CPT releases. |
| NDC, dosing, FDA label, regimen list | Event-driven | Tied to manufacturer document version + FDA label revision date + NCCN MM updates. |
Reviewer
Pending SME review. This page is staff-authored from primary sources (FDA, CMS,
manufacturer, payer documents — all linked above). Editorial review in progress. Until that review is complete, treat this as a draft reference and verify each cited
source for high-stakes claims.
Change log
- — Initial publication. ASP data: Q2 2026 (J9047 ASP+6% $56.239/mg). Manufacturer source: Amgen Assist 360 2025. FDA label most recent revision (BLA 202714). NCCN MM v.2.2026 Kd / KRd / Kdara / Kpd regimens for R/R MM. Cardiac toxicity W&P treated as boxed-warning analog. Proteasome inhibitor class context (Velcade, Boruzu, generic bortezomib, Ninlaro).
Methodology
Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File. Payer policies are read directly from each payer's published medical/pharmacy policy documents. Regimen list is verified against the current FDA label revision and NCCN MM guidelines. We do not paraphrase from billing-software vendor blogs.